Stage III melanoma: ctDNA predicts high risk for relapse in Australian study

  • Tan L & al.
  • Ann Oncol
  • 6 Feb 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In a small, prospective study, circulating tumor (ct) DNA positivity is associated with increased risk for relapse in patients with stage III cutaneous melanoma.

Why this matters

  • Baseline and postoperative ctDNA detection can inform adjuvant therapy decisions.

Key results

  • ctDNA was detected in 37% of patients.
    • 35% at baseline and 24% postoperatively.
  • 54% of patients relapsed.
  • Baseline ctDNA detection was associated with decreased relapse-free survival (RFS; HR, 2.9; P=.002) and distant metastasis-free survival (DMFS; HR, 2.9; P=.003).
  • Postoperative ctDNA detection was also associated with decreased RFS (HR, 10; P<.001 and dmfs style="list-style-type:circle;">
  • HR, 11 (P <.001 for rfs and hr dmfs in multivariate analysis.>
  • The sensitivity and specificity of postoperative ctDNA in predicting relapse at 12 months were 55% and 94%, respectively.
  • RFS and DMFS results were validated in an independent cohort.
  • Study design

    • 99 patients with stage III melanoma and somatic mutations (54% BRAF, 31% NRAS, and 15% TERT promoter, TP53, or KIT) were analyzed for ctDNA and associations with recurrence and survival outcomes.
    • The external validation cohort included 29 patients.
    • Funding: Australian National Health and Medical Research Council; Cancer Research UK; Wellcome Trust.

    Limitations

    • Small patient sample size.

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit